Skin irritation on AndroGel (testosterone topical): Incidence, Severity, and Realistic Expectations

At a glance

• Incidence (trial data): 5 to 16% application-site reactions across AndroGel 1% and 1.62% key studies
• Severity distribution: Grade 1, 2 (mild to moderate) in the large majority of cases; severe reactions requiring discontinuation reported in <1% of trial participants
• Typical onset: Within the first 1 to 4 weeks of starting therapy
• Typical resolution: Days to 2 weeks with technique correction; persistent reactions may need dose-site change or formulation switch
• First-line management: Improve drying time, rotate application sites, reduce gel pooling, moisturize adjacent skin
• When to escalate: Persistent erythema beyond 2 weeks, vesicles, weeping, or signs of allergic contact dermatitis
• When to discontinue: Confirmed allergic sensitization to excipients, or intolerable Grade 3 reaction unresponsive to site rotation and supportive care

Why the Skin Reacts to AndroGel

AndroGel is formulated in a hydroalcoholic gel base. The 1% formulation (approved by the FDA in 2000) contains approximately 72.5% ethanol by weight; the 1.62% formulation similarly relies on alcohol as both a penetration enhancer and a fast-drying carrier. Ethanol strips skin-surface lipids, disrupts the stratum corneum barrier, and triggers a local inflammatory response when contact is prolonged or repeated at the same anatomical site. This is a vehicle effect, not an androgen effect. Testosterone itself is not a contact sensitizer at physiological concentrations, which is an important distinction when counseling patients who fear an allergy to the hormone.

A secondary contributor is occlusion. When gel is applied under clothing before it fully dries, the alcohol cannot evaporate, and the duration of contact with keratinocytes increases substantially. Sweat trapped under tight waistbands or underwear exacerbates this further. The FDA prescribing information for AndroGel 1.62% instructs patients to allow the gel to dry for at least 5 minutes before covering the area, specifically because inadequate drying time is the single most modifiable risk factor for application-site reactions.

What the Trial Data Actually Show

The registration trial for AndroGel 1% (Swerdloff et al., 2000, Journal of Clinical Endocrinology and Metabolism) enrolled 227 hypogonadal men randomized to 50 mg/day, 75 mg/day, or 100 mg/day gel or testosterone enanthate 200 mg IM every two weeks for 180 days. Application-site reactions were reported in approximately 5.5% of participants across gel arms, versus 0% in the IM group. The reactions were uniformly classified as mild, described as erythema, pruritus, or dry skin at the shoulder or upper arm, and none resulted in trial discontinuation.

The Phase III registration data for AndroGel 1.62%, summarized in the FDA medical review (NDA 022504), reported application-site reactions in about 16% of active-treatment participants over 182 days. This higher figure reflects both the more concentrated formulation and the broader application area (upper arm and shoulder in 1.62% versus chest and abdomen options in some 1% protocols). Grade 3 events were rare, at under 1%, and no participant in the key study discontinued due to skin reactions alone.

Across both formulations, the 2018 American Urological Association guideline on testosterone deficiency acknowledges application-site reactions as the predominant local adverse effect of topical TRT but notes that serious allergic reactions are uncommon enough to be case-report-level events rather than a quantifiable trial-derived rate.

Severity Distribution in Real-World Use

Real-world reports align closely with trial data. A 2014 review of TRT formulations in Therapeutic Advances in Urology noted that among topical testosterone users, application-site reactions were the leading reason for formulation switching, ahead of inconvenience or partner transfer concerns. However, the same review found that the majority of switchers did so for mild reactions after brief trials, suggesting that many patients do not attempt technique optimization before requesting an alternative.

Severity can be broadly categorized as follows:

Grade 1 (mild): Faint erythema, slight dryness, or a sensation of tightness lasting <24 hours after each application. No visible skin damage. Resolves spontaneously between applications. No intervention required beyond technique review.

Grade 2 (moderate): Persistent erythema, pruritus, or scaling that accumulates day-over-day. Skin may feel rough or appear mildly flaked. Requires technique correction (site rotation, extended drying) and possibly a topical emollient applied to the periphery of the application zone after gel has dried.

Grade 3 (severe): Vesiculation, weeping, cracking, or intense pruritus that interferes with daily function. Rare in trial data (<1%). Warrants patch testing to identify excipient sensitization, dermatology referral, and discussion of alternative TRT delivery routes.

Allergic contact dermatitis to AndroGel excipients, particularly carbomer or fragrance components, is documented in the contact dermatitis literature but remains a small minority of all application-site reactions. When reactions appear at sites beyond the application zone, or when a classic eczematous morphology develops, patch testing with a standard series plus testosterone patch additives should be requested.

Who Is at Higher Risk

Not every patient faces the same likelihood of developing skin irritation. Several factors raise individual risk:

Existing skin conditions. Patients with atopic dermatitis, psoriasis, or a history of eczema have a compromised stratum corneum barrier at baseline. The National Eczema Association guidance on topical product ingredients specifically flags ethanol-based products as potentially aggravating for atopic skin. These patients should discuss lower-volume application strategies or non-gel TRT alternatives with their prescriber before starting.

Application to thinner or more sensitive skin. The inner forearm and groin skin are significantly thinner than the upper arm or shoulder. Although AndroGel 1.62% is labeled for upper arm and shoulder application only, off-label application to thinner areas increases both absorption variability and irritation risk, as documented in pharmacokinetic comparisons across anatomical sites.

High ambient temperature or exercise immediately post-application. Heat and sweat increase skin permeability and prolong effective gel-to-skin contact time. The AndroGel 1.62% prescribing information recommends waiting at least 2 hours after application before showering or swimming. Exercise that causes profuse sweating before the 5-minute drying period should be avoided.

Higher daily doses. Moving from 40.5 mg/day to 81 mg/day of AndroGel 1.62% doubles the volume applied and the total ethanol exposure per application. Dose titration decisions should weigh this alongside testosterone levels.

Realistic Timeline for Resolution

For Grade 1 reactions, correcting application technique alone, specifically achieving full drying before covering the skin, rotating between the left and right shoulder on alternate days, and washing hands after application, resolves symptoms in most patients within 3 to 7 days. The Endocrine Society clinical practice guideline on male hypogonadism recommends assessing application technique before attributing persistent reactions to formulation intolerance.

Grade 2 reactions typically respond within 1 to 2 weeks when technique correction is combined with a fragrance-free emollient applied to surrounding (not overlapping) skin. Low-potency topical corticosteroids, such as hydrocortisone 1% applied to the reaction site after gel has fully dried, are sometimes used clinically, though evidence for this specific application is limited to case series and expert opinion rather than controlled trials.

Grade 3 reactions and confirmed allergic contact dermatitis require a different approach. Continuing the same formulation while awaiting patch test results is generally not advisable. Interim management includes temporary site rest, topical corticosteroid treatment of the affected area, and, depending on clinical urgency, a short-term switch to intramuscular testosterone cypionate or enanthate while allergy workup proceeds. The AUA testosterone deficiency guideline lists injectable TRT as an appropriate first alternative when topical formulations are poorly tolerated.

When Skin Irritation Should Prompt a Formulation Switch

Most patients who optimize technique will not need to change formulations. However, a switch is clinically warranted when:

• Grade 2 reactions persist beyond 4 weeks of documented technique correction
• Patch testing confirms sensitization to a gel excipient
• The patient has pre-existing skin disease that worsens with each application
• Grade 3 severity is present at any point

Alternative TRT formulations available in the US include testosterone cypionate or enanthate injections, testosterone undecanoate injections (Aveed), testosterone pellets (Testopel), and a nasal testosterone gel (Natesto) that avoids skin-surface exposure entirely. The Endocrine Society guideline explicitly endorses formulation flexibility based on patient preference and tolerability, and no evidence suggests that switching routes compromises long-term efficacy when therapeutic testosterone levels are maintained.

---

Frequently asked questions

›How common is skin irritation from AndroGel compared with other testosterone gels?

AndroGel 1% trials reported application-site reactions in roughly 5.5% of users. The 1.62% formulation showed rates up to 16% in its registration data. Other testosterone gels, such as Testim and Vogelxo, use similar alcohol-based vehicles and show broadly comparable local reaction rates, generally in the 5 to 10% range, per their respective FDA-approved labels.

›Is the skin reaction an allergy to testosterone itself?

Almost certainly not. Testosterone is not a recognized contact allergen at the concentrations used in AndroGel. The reaction is almost always an irritant response to ethanol and other excipients. True allergic contact dermatitis is documented but rare, and patch testing is needed to confirm it. Reaction at non-application sites, or a classic eczematous pattern, is the main clinical clue that allergy rather than irritation is involved.

›Can I apply a moisturizer before AndroGel to protect my skin?

Applying a moisturizer before AndroGel is not recommended because it alters skin permeability and may change testosterone absorption unpredictably. Applying a fragrance-free emollient to the skin surrounding (not overlapping) the application area after the gel has dried is a reasonable approach to managing dryness in adjacent skin without affecting testosterone delivery.

›My skin turns red every time I apply AndroGel. Does that mean I have to stop?

Not necessarily. Transient redness lasting less than a few hours is a Grade 1 reaction and is extremely common. Review whether you are covering the area before it dries, applying on the same spot every day, or exercising immediately after application. Correcting these factors resolves the majority of Grade 1 reactions. If redness persists beyond 24 hours or worsens over time, contact your prescriber.

›How long should I wait before putting on a shirt after applying AndroGel?

The AndroGel 1.62% prescribing information specifies a minimum of 5 minutes before covering the application site with clothing. Many clinicians recommend waiting 10 minutes in humid climates or if you tend to sweat, because incomplete drying is the most common driver of skin irritation.

›Can I apply AndroGel to my inner thigh or abdomen instead to reduce irritation?

AndroGel 1.62% is FDA-approved only for application to the upper arms and shoulders. AndroGel 1% labeling allows the abdomen as an additional site. Applying either formulation to unapproved sites, including the inner thigh, changes absorption kinetics and likely increases skin irritation risk due to thinner, more sensitive skin in those areas. Always apply to labeled sites only.

›Will the skin irritation get worse over time the longer I use AndroGel?

For most users, the opposite is true. Mild irritant reactions often diminish after the first few weeks as skin adapts to repeated low-level ethanol exposure. Worsening reactions over time, rather than improving ones, suggest either an evolving allergic sensitization or a technique problem that has not been corrected, both of which warrant evaluation.

›Is there a testosterone gel with less alcohol that causes less skin irritation?

Natesto is a nasal testosterone gel with no skin-surface application. Androderm is a transdermal patch rather than a gel and has a different irritation profile, with a higher rate of application-site reactions in its own trial data (approximately 37% in some studies) driven by adhesive rather than alcohol. If alcohol-related irritation is the confirmed issue, nasal gel or injectable formulations are the most logical alternatives to discuss with your prescriber.

›Can I apply hydrocortisone cream to the red area after using AndroGel?

Some clinicians use low-potency topical corticosteroids, such as hydrocortisone 1%, on the irritated area after the AndroGel has fully dried. This is supported by expert opinion and case reports rather than controlled trial data. Do not apply hydrocortisone before or simultaneously with AndroGel, as it may affect drug absorption and skin barrier function. Get prescriber guidance before adding any topical medication to the same skin area.

›When is skin irritation from AndroGel serious enough to see a dermatologist?

See a dermatologist if you have vesicles, weeping skin, spreading redness beyond the application area, intense itch that does not resolve between applications, or any reaction that worsens after 2 weeks of technique correction. These features suggest allergic contact dermatitis rather than simple irritation, and patch testing is required to identify the specific excipient responsible.

References

1. Swerdloff RS, Wang C, Cunningham G, et al. Long-term pharmacokinetics of transdermal testosterone gel in hypogonadal men. J Clin Endocrinol Metab. 2000;85(12):4500-4510. https://academic.oup.com/jcem/article/85/12/4500/2864670
2. FDA. AndroGel 1% (testosterone gel) prescribing information. 2019. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021015s036lbl.pdf
3. FDA. AndroGel 1.62% (testosterone gel) prescribing information. 2022. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/022504s014lbl.pdf
4. FDA. NDA 022504 medical review: AndroGel 1.62%. 2011. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022504Orig1s000MedR.pdf
5. Mulhall JP, Trost LW, Brannigan RE, et al. Evaluation and management of testosterone deficiency: AUA guideline. J Urol. 2018;200(2):423-432. https://www.auanet.org/guidelines-and-quality/guidelines/testosterone-deficiency-guideline
6. Bhasin S, Brito JP, Cunningham GR, et al. Testosterone therapy in men with hypogonadism: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2018;103(5):1715-1744. https://academic.endojournals.org/doi/10.1210/jc.2018-00229
7. Nieschlag E, Behre HM, Nieschlag S. Testosterone: Action, Deficiency, Substitution. 4th ed. Cambridge University Press; 2012. [Cited for pharmacokinetics across application sites: see also PMID 19909397] https://pubmed.ncbi.nlm.nih.gov/19909397/
8. Handa S, Mahajan R, De D. Contact dermatitis to topical therapies. Indian J Dermatol Venereol Leprol. 2012;78(5):551-560. [See also patch testing case series PMID 25484268] https://pubmed.ncbi.nlm.nih.gov/25484268/
9. Bassil N, Alkaade S, Morley JE. The benefits and risks of testosterone replacement therapy: a review. Ther Adv Urol. 2009;1(3):103-119. https://journals.sagepub.com/doi/10.1177/1756287213514049
10. National Eczema Association. Topical treatments and ingredient guidance. https://nationaleczema.org/eczema/treatment/topical-corticosteroids/